



**A COMPREHENSIVE REVIEW ON GENE THERAPY**

**Ankit Singh Chauhan\*, Ashwani Kumar and N. Trilochana**

Institute of Pharmaceutical Sciences and Research, Unnao, Uttar Pradesh, India – 209859.

**\*Corresponding Author: Ankit Singh Chauhan**

Institute of Pharmaceutical Sciences and Research, Unnao, Uttar Pradesh, India – 209859.

Article Received on 02/05/2023

Article Revised on 22/05/2023

Article Accepted on 12/06/2023

**ABSTRACT**


The Gene therapy became possible through the advances of genetics and bioengineering that enabled manipulating vectors for delivery of extrachromosomal material to focus on cells. The ability to form site-specific modifications to the human genome has been an objective in medicine since the popularity of the gene because the basic unit of heredity. Thus, gene therapy is known because the ability of genetic improvement through the correction of altered genes or site-specific modifications that focus on therapeutic treatment. One of the most focuses of this system is that the optimization of delivery vehicles that are mostly plasmids, nanostructured or viruses. The viruses are more often investigated thanks to their excellence of invading cells and inserting their genetic material. However, there's great concern regarding exacerbated immune responses and genome manipulation, especially in germ line cells. In vivo studies in in vegetative cell showed satisfactory results with approved protocols in clinical trials.

**KEYWORDS:** Gene therapy, Genetic Vectors, Gene transfer, Herpes simplex viruses.

**INTRODUCTION**

In the past few years, gene therapy has come to the central stage worldwide. The ability to form local modifications within the human genome has been the target of drugs since the knowledge of DNA because the basic unit of heredity. Gene therapy is known because the capacity for gene improvement by means of the correction of altered (mutated) genes or site-specific modifications that have therapeutic treatment as target. Further on, different strategies are described, which are often used for this purpose.<sup>[1]</sup> Currently, gene therapy is an area that exists predominantly in research laboratories, and its application is still experimental.<sup>[2]</sup> Most trials are conducted within the US, Europe, and Australia. The approach is broad, with potential treatment of diseases caused by gene disorders (cystic fibrosis, hemophilia, dystrophy, and red blood cell anemia), acquired genetic diseases like cancer, and certain viral infections, such as AIDS. One of the foremost often used techniques consists of recombinant deoxyribonucleic acid technology, during which the gene of interest or healthy gene is inserted into a vector, which may be a plasmid, nanostructured, or viral; the latter is the most often used due to its efficiency in invading cells

and introducing its genetic material. On a few gene therapy protocols are summarized, approved and published for clinical use, exemplifying the disease, the target, and the type of vector used. Although several protocols are successful, the gene therapy process remains complex, and lots of techniques need new developments. The specific body cells that require treatment should be identified and accessible. A way to effectively distribute the gene copies to the cells must be available, and the diseases and their strict genetic bonds need to be completely understood.<sup>[3,4]</sup> There is also the important issue of the target cell type of gene therapy that currently is subdivided into two large groups: gene therapy of the germline and gene therapy of somatic cells. The modifications are hereditary and expire to subsequent generations. Any modification and any effects are restricted only to that patient and are not inherited by future generations.<sup>[5]</sup> Although genes get tons of attention, it is the proteins that perform most life functions and even structure the bulk of cellular structures. When genes are altered so that the encoded proteins are unable to carry out their normal functions, genetic disorders can result.<sup>[6,7]</sup>




**Fig. 1: Gene therapy.**

### What is a gene?

A gene is the basic physical and functional unit of heredity. Genes are made up of DNA. Some genes act as instructions to make molecules called proteins. However, many genes do not code for proteins. In humans, genes vary in size from a few hundred DNA

bases to more than 2 million bases. An international research effort called the Human Genome Project, which worked to determine the sequence of the human genome and identify the genes that it contains, estimated that humans have between 20,000 and 25,000 genes.



**Fig. 2: Structure of gene.**

### How does gene therapy work?

The Gene therapy works by altering the genetic code to recover the functions of critical proteins. Proteins are the workhorses of the cell and the structural basis of the body's tissues. The instructions for making proteins are carried in a person's genetic code, and variants (or mutations) in this code can impact the production or function of proteins that may be critical to how the body works. Fixing or compensating for disease-causing genetic changes may recover the role of these important proteins and allow the body to function as expected. Gene therapy can compensate for genetic alterations in a couple different ways.

- The Gene transfer therapy introduces new genetic material into cells. If an altered gene causes a necessary protein to be faulty or missing, gene transfer therapy can introduce a normal copy of the gene to recover the function of the protein. Alternatively, the therapy can introduce a different gene that provides instructions for a protein that

helps the cell function normally, despite the genetic alteration.

- The Genome editing is a newer technique that may potentially be used for gene therapy. Instead of adding new genetic material, genome editing introduces gene-editing tools that can change the existing DNA in the cell. Genome editing technologies allow genetic material to be added, removed, or altered at precise locations in the genome. CRISPR-Cas9 is a well-known type of genome editing.

### History and Future of gene therapy

The first patient was successfully treated on 14th September 1990, at National Institutes of Health's Clinical Center (NHICC), Bethesda, Maryland. Dr. W. French Anderson and his colleagues at the clinic, administered the proceedings. White blood cells were extracted from the body. After the implantation of genes that produce ADA, the cells were transferred back to the

patient body. Considerable improvement within the system of the girl was noticed.

#### Advantages of gene therapy<sup>[8,9]</sup>

- 1) Gene therapy offers a true cure, and not simply palliative or symptomatic treatment.
- 2) Gene therapy may be the only effective way of addressing some genetic diseases.
- 3) By the transmission of prevention of disease genes, the expense and risk of somatic cell therapy for multiple generations is avoided.
- 4) Drug are responds to the reproductive health needs of prospective parents at risk for transmitting serious genetic diseases.
- 5) Scientific community has a right to free inquiry, within the bounds of acceptable human research.

#### Disadvantages of gene therapy

- 1) Gene therapy experiments would involve too much scientific uncertainty and clinical risks, and the long-term effects of such therapy are unknown.
- 2) Gene therapy would open the door to attempts at altering human traits not associated with disease, which could exacerbate problems of social discrimination.
- 3) As germ-line gene therapy involves research on early embryos and effects their offspring, such research essentially creates generations of unconsenting research subjects.
- 4) Gene therapy is very expensive, and will never be cost effective enough to merit high social priority.
- 5) Gene therapy would violate the rights of subsequent generations to inherit a genetic endowment that has not been intentionally modified.

The ethical issues posed by both somatic and germ-line gene therapies are international in scope. The documents listed below serve to demonstrate the variety of reactions to gene therapy, and to illuminate the complexity of this continuing public debate.

#### Types of gene therapy

- 1) **Germ line gene therapy** – Germ Line gene therapy is entail injecting foreign genes into fertilized eggs or in sperms producing cells, which will then pass any genetic changes to future generations as well. However, although it has potential for preventing inherited disease, this form of gene therapy is extremely controversial and currently very little research is being done in this area, both for technical and ethical reasons.<sup>[10]</sup>
- 2) **Somatic gene therapy** – Somatic gene therapy is involves introducing a "good" gene into targeted cells with the end result of treating the patient - but not the patient's future children because these genes

do not get passed along to offspring. In other words, even though some of the patient's genes may be altered to treat a disease, the likelihood remains that the same disease will affect the patient's children. This is the form of gene therapy that is being done at most genetics' laboratories throughout the world.<sup>[10]</sup>

#### Target cells for gene therapy<sup>[11]</sup>

- 1) Peripheral blood lymphocytes
- 2) Hemopoietin stem cells
- 3) Fibroblasts
- 4) Hepatocytes
- 5) Keratinocytes
- 6) Skeletal muscle myoblasts
- 7) Airway epithelial cells
- 8) Vascular endothelial cells
- 9) Tumor cells

#### Methods for gene therapy<sup>[12]</sup>

- 1) Physical
  - a) Direct injection of DNA
  - b) Liposome-mediated DNA transfer
  - c) Calcium phosphate transfection-
  - d) Electroporation
- 2) Retrovirus vectors
- 3) Other viral vectors
- 4) Targeted gene transfer via receptors
- 5) Artificial chromosomes
- 6) Site-directed recombination
- 7) Activation of genes of related function.

#### Vectors in gene therapy

In most gene therapy studies, a normal gene is inserted into the genome to replace an abnormal, disease-causing gene. A carrier molecule called a vector is used to deliver the therapeutic gene to the patient's target cells. Currently, the most common vector is a virus that has been genetically altered to carry normal human DNA. Viruses have evolved a way of encapsulating and delivering their genes to human cells in a pathogenic manner. Scientists have tried to take advantage of this capability and manipulate the virus genome to remove disease-causing genes and insert therapeutic genes.<sup>[13-15]</sup>

The different types of viruses used as gene therapy vectors is given below-

- **Retroviruses** - A class of viruses that can create double-stranded DNA copies of their RNA genomes. Genome copy can be integrated into the chromosomes of host cells. Human immunodeficiency virus (HIV) is a retrovirus.
- **Adenoviruses** - A class of viruses with double-stranded DNA genomes that cause respiratory, intestinal, and eye infections in humans. The virus that causes the common cold is an adenovirus.




Fig. 3: Gene therapy using an adenovirus vector.

- **Adeno-associated viruses** - A small class, single-stranded DNA viruses that can insert their genetic material at a specific site on chromosome 19.
- **Herpes simplex viruses** - A class of double-stranded DNA viruses that infect a particular cell type, neurons. The Herpes simplex virus type 1 is a common human pathogen that causes cold sores.

#### Approaches of gene therapy<sup>[16]</sup>

1. Gene modification
  - Replacement therapy
  - Corrective Gene therapy
2. Gene transfer
  - Physical
  - Chemical
  - Biological
3. Gene transfer in specific cell line
  - Somatic gene therapy
  - Germ line gene therapy
4. Eugenic approach (Gene insertion)

#### Applications of gene therapy

This therapy is more useful to have the greatest success with diseases that are caused by single gene defects. By the end of 1993, gene therapy had been approved for use on such diseases as severe combined immune deficiency, familial hypercholesterolemia, cystic fibrosis, and Gaucher's disease. Most protocols to date are aimed toward the treatment of cancer; a few are also targeted toward AIDS. Numerous disorders are discussed as candidates for gene therapy: Parkinson's and Alzheimer's diseases, arthritis, and heart disease. The Human Genome Project, an ongoing effort to identify the location of all the genes in the human genome, continues to identify genetic diseases.<sup>[17,18]</sup>

#### Eve Nichols describes the criteria for selection of disease for human gene therapy<sup>[19]</sup>

- 1) The disease is an incurable, life-threatening disease;
- 2) Organ, tissue and cell types affected by the disease have been identified
- 3) The normal counterpart of the defective gene has been isolated and cloned
- 4) The normal gene can be introduced into a substantial sub fraction of the cells from the affected tissue; or

that introduction of the gene into the available target tissue, such as bone marrow, will somehow alter the disease process in the tissue affected by the disease.

- 5) The gene can be expressed adequately (it will direct the production of enough normal protein to make a difference)
- 6) Techniques are available to verify the safety of the procedure.

#### Future of gene therapy

- The nanotechnology and gene therapy yields treatment to torpedo cancer. March, 2009. The School of Pharmacy in London is testing a treatment in mice, which delivers genes wrapped in nanoparticles to cancer cells to target and destroy hard-to-reach cancer cells.
- The results of world's first gene therapy for inherited blindness show sight improvement. 28 April 2008. UK researchers from the UCL Institute of Ophthalmology and Moorfield's Eye Hospital NIHR Biomedical Research Centre have announced results from the world's first clinical trial to test a revolutionary gene therapy treatment for a type of inherited blindness.
- The researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, successfully reengineer immune cells, called lymphocytes, to target and attack cancer cells in patients with advanced metastatic melanoma. This is the first time that gene therapy is used to successfully treat cancer in humans. See *New Method of Gene Therapy Alters Immune Cells for Treatment of Advanced Melanoma*.
- The Gene therapy is effectively used to treat two adult patients for a disease affecting non lymphocytic white blood cells called myeloid cells. Myeloid disorders are common and include a variety of bone marrow failure syndromes, such as acute myeloid leukemia. The study is the first to show that gene therapy can cure diseases of the myeloid system. See *Gene Therapy Appears to Cure Myeloid Blood Diseases in Groundbreaking International Study*.
- The University of California, Los Angeles, research team gets genes into the brain using liposomes coated in a polymer called polyethylene glycol (PEG).

The transfer of genes into the brain is a significant achievement because viral vectors are too big to get across the "blood-brain barrier." This method has potential for treating Parkinson's disease. See Undercover Genes Slip into the Brain.

- The RNA interference or gene silencing may be a new way to treat Huntington's. Short pieces of double-stranded RNA (short interfering RNAs or RNAs) are used by cells to degrade RNA of a particular sequence. If an RNA is designed to match the RNA copied from a faulty gene, then the abnormal protein product of that gene will not be produced. See Gene Therapy May Switch off Huntington's.
- The new gene therapy approach repairs errors in messenger RNA derived from defective genes. Technique has potential to treat the blood disorder thalassemia, cystic fibrosis, and some cancers. See Subtle Gene Therapy Tackles Blood Disorder.

### CONCLUSION

By gene therapy different types of genetic disorder are cured. In case of cystic fibrosis, Diabetes, AIDS, Hepatitis melanoma, Alzheimer, Parkinson's diseases etc. In case of Parkinson's disease one trial is done Neurologic a biotech company announced that they have successfully completed its landmark Phase-I trial of gene therapy for Parkinson's disease. Twelve patient study with four patients in each of three dose escalating cohorts. All procedures were performed under local anesthesia and all 12 patients were discharged from the hospital within 48 hours of the procedure, and followed for 12 months. Primary outcomes of the study design, safety and tolerability, were successfully met. There were no adverse events reported relating to the treatment. Steps involved in treatment of Parkinson's disease. In case of diabetes gene therapy also play a good role. Replacing a mutated gene that causes disease with a healthy copy of the gene. Inactivating, or "knocking out," a mutated gene that is functioning improperly. Introducing a new gene into the body to help fight a disease.

### REFERENCE

1. Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. *N England J Med*, 2014; 370(10): 901–910.
2. Linden R. Gene therapy: what it is, what it is not and what it will be. *Estud Av*, 2010; 24(70): 31–69.
3. Ginter EK. Gene therapy of hereditary diseases. *Vopr Med Khim*, 2000; 46(3): 265–278.
4. Mishra S. Human gene therapy: a brief overview of the genetic revolution. *J Assoc Physicians India*, 2013; 61(2): 127–133.
5. Mathews QL, Curiel DT. Gene therapy: human germline genetics modifications-assessing the scientific, socioethical, and religious issues. *South Med J*, 2007; 100(1): 98–100.
6. Bank A. Human somatic cell gene therapy. *Bioassays*, 1996; 18(12): 999–1007.
7. Kaufmann KB, Being H, Gaily A, Schambach A, Graz M. Gene therapy on the move. *EMBO Mol Med*, 2013; 5(11): 1642-1661.
8. McCain J. The Future of Gene Therapy. *Biotechnology Health*, 2005; 2(3): 52-54, 56-60.
9. Jafarlou M, Baradaran B, Saedi TA, Jafarlou V, Shanehbandi D, Maralani M, et al. An overview of the history, applications, advantages, disadvantages and prospects of gene therapy. *J Biol Reglue Homiest Agents*, 2016; 30(2): 315-2.
10. Moss JA. Gene therapy review. *Radial Technol*, 2014; 86(2): 155-80, 181-4.
11. Miller N, Vile R. Targeted vectors for gene therapy. *FASEB J*, 1995; 9(2): 190-9.
12. Mali S. Delivery systems for gene therapy. *Indian J Hum Genet*, 2013; 19(1): 3-8.
13. Gardlík R, Pálffy R, Hodosy J, Lukacs J, Turna J, Celiac P. Vectors and delivery systems in gene therapy. *Med Sci Monit*, 2005; 11: RA110-21.
14. Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. *Pharmacology Therapy*, 1998; 80(1): 35-47.
15. Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. *Adv Biomed Res*, 2012; 1: 27.
16. Unnova F.D., Rebar E.J., Holmes M.C., Zhang H.S., Gregory P.D. Genome editing with engineered zinc finger nucleases, 2010; 636-646.
17. Anderson WF. Human gene therapy. *Nature*, 1998; 392(6679): 25-30.
18. Mulherkar R. Gene therapy for cancer. *Curr Sci*, 2001; 81: 555-60.
19. Nichols, Eve K. *Human Gene Therapy*. Cambridge, MA: Harvard University Press, 1988.